ReviewDiseases (Basel, Switzerland)2026
Suicide Risk and Associated Factors in Patients with Pancreatic Cancer: A Systematic Review.
Review in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND/
objectivesPancreatic cancer (PC) is characterized by poor survival and a substantial psychological burden. Growing evidence suggests that individuals diagnosed with PC are at an increased risk of suicide. This systematic review aimed to synthesize the available evidence on suicide risk among patients with PC and to identify factors associated with increased vulnerability.
methodsFollowing the PRISMA 2020 guidelines, a systematic review of the PubMed/MEDLINE and Scopus databases was conducted in August 2026. Of the 1015 records initially identified, 23 studies published between 2010 and July 2026 were included. Eligible studies specifically examined suicide risk among patients with PC using registry-based, administrative, or death certificate data. Risk of bias was assessed using the ROBINS-E tool.
resultsMost included studies reported a higher suicide risk among patients with PC compared with the general population and, in many analyses, compared with patients with other cancer types. Large population-based studies generally reported standardized mortality ratios of approximately 2 to 11, although substantially higher estimates were observed in selected populations and specific subgroups. Suicide risk was particularly elevated during the early post-diagnosis period (with several studies identifying the greatest excess risk within the first two months following diagnosis), remained elevated throughout the first year and gradually declined thereafter. Male sex emerged as the most consistently demonstrated risk factor for suicide, while associations with unmarried status were observed across several studies but were derived largely from partially overlapping SEER-based cohorts. Additional evidence suggests a potential role for social vulnerability and poor prognostic factors.
conclusionsDespite the predominantly observational nature of the available evidence, the consistency of the findings highlights the importance of increased awareness of suicide vulnerability among patients with PC and supports consideration of psychosocial assessment and mental health support within routine pancreatic cancer care. Future prospective studies are needed to better characterize high-risk patients and to inform targeted suicide prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.